Skip Page Header

Home > Addiction to transmucosal fentanyl: is it a cause for concern in cancer pain management?

Cahill, Kathleen and Shehab, Ruqaya Mohsen and Lowney, Aoife and McQuillan, Regina (2015) Addiction to transmucosal fentanyl: is it a cause for concern in cancer pain management? Palliative medicine , 29 , (9) , pp. 861-862. DOI: 10.1177/0269216315593452.


Transmucosal fentanyl (TMF) is a µ-receptor agonist used in the management of pain in patients with cancer.1 Current licensing restrictions allow for prescribing of TMF only in patients with cancer who are opioid tolerant and taking the equivalent of 60 mg oral morphine daily. In the United States, prescribers and dispensers of TMF must be specifically certified and enrolled to do so. It has previously been reported that off-label use of TMF can be as high as 90%.....

Item Type
Article
Publication Type
Irish-related, Article
Drug Type
Opioid
Date
30 June 2015
Identification #
DOI: 10.1177/0269216315593452
Page Range
pp. 861-862
Publisher
Sage
Volume
29
Number
9
EndNote
Related URLs

Click here to request a copy of this literature (must be logged in)

Repository Staff Only: item control page